Class of antipsychotic and duration of psychiatricinpatient treatment: an 8-year ecological study
DOI:
https://doi.org/10.25118/2236-918X-8-1-1Keywords:
Antipsychotics, length of stay, inpatientAbstract
Objective: Studies have shown changes in antipsychoticprescription patterns over the last two decades, withemphasis on the increased use of atypical antipsychoticsas compared to typical ones. The objective of this studywas to longitudinally evaluate trends in the prescriptionof typical and atypical antipsychotics (except clozapine)and their association with the mean length of stay in apsychiatric hospital. Methods: This was an ecological study. The pharmacyand the Medical Archive and Statistics Service ofInstituto de Psiquiatria de Santa Catarina provided dataon antipsychotic prescriptions and mean hospital stayfrom January 2007 to December 2014. Simple andmultiple linear regression analyses were used to evaluatethe association between independent variables and theoutcome.Results:Over the 8 years of study, there was anincrease in the prescription of atypical antipsychotics(coefficient B = 0.0037; 95% confidence interval [95%CI]0.0033 to 0.0041; p < 0.001) and a reduction in theprescription of typical antipsychotics (coefficient B =-0.009; 95%CI -0.01 a -0.008; p < 0.001), measuredin defined daily doses (DDD). There was no associationbetween prescription of typical/atypical antipsychoticsand mean monthly hospitalization stay. There was anincrease in hospital occupancy rate in the period, withfrequent overcrowding. Conclusion: The worldwide pattern of increasedprescription rates of atypical antipsychotics was alsofound in this study. There was no association betweenthis increase and mean length of hospital stay. Althoughthis was not an objective of this study, the overcrowdingobserved deserves the attention of public managers.
Downloads
Metrics
References
Jeppesen RM, Christensen T, Vestergaard CH. Changes in the utilization of psychiatric hospital facilities in Denmark by patients diagnosed with schizophrenia from 1970 through 2012: The advent of ‚revolving door‘ patients. Acta Psychiatr Scand. 2016;133:419-25.
Sim K, Su HC, Fujii S, Yang SY, Chong MY, Ungvari G, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001
and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol. 2009;67:110-7.
Medel-Herrero A, Amate JM, Saz-Parkinson Z, Gómez-Beneyto M. Changing trends in hospitalization rates associated with psychosis: Spain, 1980-2009. Soc Psychiatry Psychiatr Epidemiol. 2015;50:1843-55.
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al. Cost-effectiveness of secondgeneration antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080-9.
Shen WW. A history of antipsychotic drug development. Compr Psychiatry. 1999;40:407-14.
Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol. 2003;56:569-75.
Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia--changes and challenges. Int Rev Psychiatry. 2008;20:460-8.
Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns in schizophrenia outpatients: analysisof data from a German health insurance fund. Pharmacopsychiatry. 2009;42:66-71.
Prah P, Petersen I, Nazareth I, Walters K, Osborn D. National changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United Kingdom. Pharmacoepidemiol Drug Saf. 2012;21:161-9.
Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci. 2004;58:61-7.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in
schizophrenia: a multiple-treatments metaanalysis. Lancet. 2013;382:951-62.
Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and metaanalysis of randomized trials. Am J Psychiatry. 1999;156:990-9.
Johnsen E. Review: metabolic side effects of second-generation antipsychotics. Evid Based Ment Health. 2011;14:47.
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment – 2018. Oslo: Norwegian
Institute of Public Health; 2017. https://www.whocc.no/filearchive/publications/guidelines.pdf
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1-44.
Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009;117:S26-43.
Sim K, Su A, Leong JY, Yip K, Chong MY, Fujii S, et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry. 2004;37:175-9.
Kendall T. The rise and fall of the atypical antipsychotics. Br J Psychiatry. 2011;199:266-8.
Masan PS. Atypical antipsychotics in the treatment of affective symptoms: a review. Ann Clin Psychiatry. 2004;16:3-13.
Wysowski DK, Baum C. Antipsychotic drug use in the United States, 1976-1985. Arch Gen Psychiatry. 1989;46:929-32.
Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents?
Am J Psychiatry. 2002;159:103-8.
Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.
Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23:2305-12.
Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, et al. Adherence to treatment with antipsychotic medication and health
care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-9.
Correll CU, De Hert M. Antipsychotics for acute schizophrenia: making choices. Lancet. 2013;382:919-20.
Downloads
Published
How to Cite
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
